



英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation,
the Chinese original shall prevail.

2023 第一季度报告

The First Quarter Report in 2023

甘李药业股份有限公司
GAN & LEE PHARMACEUTICALS.
股票代码：603087
STOCK CODE: 603087

目 录

Contents

重要内容提示 Important Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	12
三、其他提醒事项 III Other Reminders	15
四、季度财务报表 IV Quarterly Financial Statements	17

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all directors of the Company warrant that the contents of this announcement do not contain any false statements, misleading statements or material omissions and accept legal responsibility for the truthfulness, accuracy and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人(会计主管人员)周丽保证季度报告中财务信息的真实、准确、完整。

第一季度财务报表是否经审计

是 否

Important notes:

The Board of Directors, the Supervisory Committee and the directors, supervisors and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, and assume individual and joint legal responsibility.

Gan Zhongru (Legal Representative), Sun Cheng (Chief Accountant) and Zhou Li (Head of Accounting Department) hereby certify that the financial report set out in the semi-annual report is true, accurate and complete.

Whether the first quarter financial statements are audited

Yes No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目 Items	本报告期 The reporting period	本报告期比上年同期增减 变动幅度(%) Change in the reporting period over the same period of the previous year (%)	
营业收入 Operating income	557,999,537.96	-19.13	
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	49,223,261.29	-56.55	
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after deduction of non-recurring profits or losses	30,086,854.49	-81.09	
经营活动产生的现金流量净额 Net cash flows from operating activities	-16,260,120.77	-106.98	
基本每股收益(元/股) Basic earnings per share (RMB/share)	0.09	-55.00	
稀释每股收益(元/股) Diluted earnings per share (RMB/share)	0.09	-55.00	
加权平均净资产收益率(%) Weighted average return on net assets (%)	0.51	减少0.60个百分点 Decrease by 0.6%	
	本报告期末 At the end of this reporting period	上年度末 At the end of last year	本报告期末比上年度末增 减变动幅度(%) Change from previous year-end at the end of this report (%)
总资产 Total Assets	10,595,877,206.40	10,606,912,380.06	-0.10
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company	9,645,460,223.51	9,585,802,149.50	0.62

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring gain or loss

单位：元 币种：人民币
Unit: RMB

项目	Items	本期金额 Current amount	说明 Note
非流动资产处置损益	Profit or loss from disposal of non-current assets	140,716.06	
计入当期损益的政府补助，但与公司正常经营业务密切相关，符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外	Government grants recognized in profit or loss other than grants which are closely related to the Company's business and are either in fixed amounts or determined under quantitative methods in accordance with the national standard	4,767,824.97	
除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债产生的公允价值变动损益，以及处置交易性金融资产、衍生金融资产、交易性金融负债、衍生金融负债和其他债权投资取得的投资收益	Profit or loss on changes in the fair value of financial assets held for trading, derivative financial assets, held for trading financial liabilities and derivative financial liabilities and investment income on disposal of financial assets held for trading, derivative financial assets, held for trading financial liabilities, derivative financial liabilities and other debt investments, other than those used in the effective hedging activities relating to normal operating business	19,284,666.31	
除上述各项之外的其他营业外收入和支出	Other non-operating income or expenses than the above items	-2,135,464.20	
其他符合非经常性损益定义的损益项目	Other losses and profits conforming to the definition of non-recurring profit and loss	527,443.17	
减：所得税影响额	Deduct: Amount affected by income tax	3,448,779.51	
少数股东权益影响额(税后)	Amount affected by non-controlling interests(after tax)		
合计	Total	19,136,406.80	

将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项目的情况说明

适用 不适用

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies Offering Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

Applicable Not Applicable

(三) 主要会计数据、财务指标发生变动的情况、原因

(III) The main accounting data, financial indicators change, the reasons of change

√ 适用 □ 不适用

√ Applicable □ Not Applicable

项目名称 Items	变动比例 (%) Percentage of change (%)	主要原因 Main Reason
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	-56.55	本报告期归属于上市公司股东的净利润较上年同期减少0.64亿元，降幅为56.55%，主要原因系营业收入下降(具体原因见表格下方说明)及销量增长带来的营业成本增加所致。 The net profit attributable to shareholders of the listed company for the reporting period decreased by RMB 0.06 billion, or reduced by 56.55%, compared with the same period of the previous year, mainly due to the decrease in operating revenue (please refer to the explanation below the table for the specific reasons) and the increase in operating costs brought about by the increase in sales volume.
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after deduction of non-recurring profits or losses	-81.09	同上 Ditto
基本每股收益 Basic earnings per share	-55.00	同上 Ditto
稀释每股收益 Diluted earnings per share	-55.00	同上 Ditto
经营活动产生的现金流量净额 Net cash flows from operating activities	-106.98	本报告期经营活动产生的现金流量净额较上年同期减少2.49亿元，降幅为106.98%，主要原因系集采后营业收入规模下降，销售商品收到的现金减少所致。 The net cash flows from operating activities in the reporting period decreased by RMB 0.02 billion, or reduced by 106.98%, compared with the same period last year, mainly due to the decrease in the scale of business income after collection and the decrease in cash received from the sale of goods.

说明：

Note:

本报告期营业收入下降原因：

The reasons for the decrease in operating income in the reporting period:

本报告期，营业收入为5.58亿元，较上年同期减少1.32亿元。其中，公司国内销售收入较上年同期减少1.58亿元，主要系2022年5月开始执行集采，集采后公司国内制剂价格下降较大。集采后，公司国内制剂销量增长显著，基本抵消了价格下降对收入的影响。本报告期，海外市场不利因素日趋减弱，公司积极恢复海外业务。公司国际销售收入较上年同期增加192.64%。

During the reporting period, operating revenue was RMB 558 million, a decrease of RMB 132 million compared with the previous year. Among them, the company's domestic sales revenue decreased by RMB 158 million compared with the previous year, mainly due to the implementation of the centralized procurement in May 2022, and the price of the company's domestic formulations decreased significantly after the centralized procurement. After the centralized procurement, the company's domestic formulation sales grew significantly, almost offsetting the impact of the price decline on revenue. During the reporting period, the adverse factors in overseas markets are weakening, and the company is actively resuming overseas business. The company's international sales revenue increased by 192.64% compared with the same period of the previous year.

单位：万元
Unit: RMB'0,000

分地区 By Region	2023年第一季度 营业收入 First quarter of 2023 Operating income	2022年第一季度 营业收入 First quarter of 2022 Operating income	同期变动(%) YOY (%)
国内-销售收入 Domestic - sales revenue	51,549.02	67,358.84	-23.47
国际-销售收入 International - sales revenue	3,845.18	1,313.97	192.64
国际-特许经营权服务收入 International - Pre-franchise services revenue	405.76	326.28	24.36
营业收入合计 Total operating income	55,799.95	68,999.09	-19.13

本报告期国内制剂收入变动情况：

本报告期，国内制剂产品收入较上年同期减少1.61亿元。2023年，胰岛素集采持续推进，公司借带量采购之势，国内制剂产品得到快速放量，销量增长对收入的正向影响基本抵消了价格下降对收入的影响。本报告期，国内制剂产品价格下降对销售收入的影响(简称“价格影响”)为-9.13亿元、国内制剂产品销量增长对销售收入的影响(简称“销量影响”)为7.52亿元。其中，非长秀霖系列产品(包括速秀霖®、速秀霖®25、速秀霖®预填充、锐秀霖®、锐秀霖®30和普秀霖®30)的销量影响已超过价格影响，非长秀霖系列产品营业收入同比增长155.33%。

Changes in domestic preparations sales revenue during the reporting period:


During the reporting period, revenue from domestic preparations products decreased by RMB 161 million compared with the previous year. In 2023, insulin procurement with quantity continued to be promoted, and the Company took advantage of the centralized procurement to rapidly increase the volume of domestic preparations products, the positive impact of sales growth on revenue basically offset the impact of price decline on revenue. During the reporting period, the impact of price decrease of domestic preparations products on sales revenue ("price impact") was RMB -913 million, and the impact of sales growth of domestic preparations products on sales revenue ("sales impact") was RMB 752 million. Among them, the sales impact of non- Basalin series products (including Prandilin™, Prandilin™25, Prandilin®ElasPen, Rapilin®, Rapilin®30 and Similin®30) exceeded the price impact, and the operating income of non- Basalin series products increased by 155.33% year-on-year.

国内制剂收入变动因素分析图:

Analysis of domestic formulation revenue change factors:

单位: 亿元

Unit: 100 million RMB



注释: 销量影响 = (2023年一季度销售量 - 2022年一季度销售量) * 2022年一季度平均单价; 价格影响 = (2023年一季度平均价格 - 2022年一季度平均价格) * 2023年一季度销售量。

Note: Volume impact = (Q1 2023 sales - Q1 2022 sales) * Q1 2022 average unit price; Price impact = (Q1 2023 average price - Q1 2022 average price) * Q1 2023 sales.

(1) 中标价格下降

(1) Decrease in winning price

公司胰岛素集采中, 公司六款产品均高顺位中标, 中标产品价格下降, 其中占公司营业收入比重最大的产品——甘精胰岛素注射液(长秀霖®)的价格下降幅度在60%以上, 对公司国内制剂产品营业收入影响较大。公司胰岛素产品在集采中标前和中标后价格如下:

The price of the winning products decreased, and the price of the product that accounts for the largest proportion of the company's operating income, Insulin glargine injection (Basalin®), decreased by more than 60%, which had a large impact on the operating income of the company's domestic preparations. The prices of the company's insulin products before and after winning the tender in the collection of tenders are as follows:

产品名称 Product name	集采前市场价格(元/支) Pre-centralized procurement price(yuan/unit)	集采中标价格(元/支) Pre-centralized procurement bid-winning price(yuan/unit)	价格降幅 Change ratio
甘精胰岛素注射液(商品名“长秀霖®”) Insulin glargine injection (Basalin®)	143.97	48.71	66%
赖脯胰岛素注射液(商品名“速秀霖®”) Insulin lispro injection (Prandilin™)	60.00	23.98	60%
精蛋白锌重组赖脯胰岛素混合注射液(25R) (商品名“速秀霖®25”) Mixed protamine zinc recombinant human insulin lispro injection (25R) (Prandilin™25)	60.00	28.88	52%
门冬胰岛素注射液(商品名“锐秀霖®”) Insulin aspart injection (Rapilin®)	59.80	19.98	67%
门冬胰岛素30注射液(商品名“锐秀霖®30”) Insulin aspart 30 injection (Rapilin®30)	59.63	24.56	59%
精蛋白人胰岛素混合注射液(30R)(商品名 “普秀霖®30”) Mixed protamine human insulin injection (30R) (Similin®30)	43.81	17.89	59%

注释：集采前市场价格为公司整理的集采中标前终端市场平均价(含税)；集采中标价格为含税价格。

Note: The pre-collective market price is the average price (including tax) of the terminal market before the collection of winning bids collated by the company; the winning price of the collection of bids is the price including tax.

(2) 销量增长迅速

(2) Rapid growth in sales

2023年一季度公司继续执行带量采购，自公司在2022年5月胰岛素集采落地执行后，为让甘李胰岛素产品快速进入更多医疗机构、快速推进市场覆盖，公司不断扩增营销团队规模，加大学术推广力度。通过上年的积极推广活动，公司国内制剂销量增长显著。本报告期，公司国内胰岛素制剂产品销量同比增长173.98%。其中，公司长秀霖系列产品销量同比增长59.63%；公司非长秀霖系列产品销量同比增长552.36%，占国内制剂收入的比例从去年同期的11.07%提升至37.43%，优化了公司产品结构，


In the first quarter of 2023, the company will continue to carry out mass procurement. Since the implementation of insulin collection in May 2022, the company has continuously expanded the scale of marketing team and intensified academic promotion in order to rapidly introduce Ganlee's insulin products into more medical institutions and rapidly promote market coverage. Through last year's active promotion, the Company's domestic formulation sales grew significantly. During this reporting period, the sales of domestic insulin preparations increased by 173.98% year-on-year. Among them, the sales volume of the company's Basalin® series products increased by 59.63% year-on-year; the sales volume of the company's non- Basalin® series products increased by 552.36% year-on-year, accounting for 37.43% of the domestic formulation revenue from 11.07% in the same

也标志着公司非长秀霖系列产品已更好地满足多样化的市场需要。同时，有助于公司已进入临床阶段的胰岛素复方制剂GZR101、第四代胰岛素类似物GZR4和新型长效胰高血糖素样肽-1受体激动剂类药物 (GLP-1RA) GZR18项目在获批上市后更好地进入市场。上年扩增的营销团队与加大学术推广的营销策略带来本季度销量显著增长。未来，公司将会持续提升销售费用投入效率，做好产品学术推广工作，更加倾向于向基层市场下沉且随着产品销量的提升，销售收入同步增长，销售费用率有可能进一步降低。销售费用率已从2022年度的63.46%降低至本报告期的40.27%。

period last year, optimizing the company's product structure and signifying that the company's non- Basalin® series products have been better able to meet the diversified market needs. At the same time, it will help the company's insulin combination GZR101, fourth-generation insulin analogue GZR4 and new long-acting glucagon-like peptide-1 receptor agonist class (GLP-1RA) GZR18, which have entered the clinical stage, to better enter the market after being approved. Last year's expanded marketing team and marketing strategy of increasing academic promotion resulted in significant sales growth in the quarter. In the future, the company will continue to improve the efficiency of sales expense investment, do a good job of academic promotion of products, and be more inclined to sink to the grassroots market. With the increase in product sales, the cost of sales ratio is likely to continue to decrease in line with the growth in sales revenue. The selling expense ratio has decreased from 63.46% in 2022 to 40.27% in the current reporting period.

国内制剂产品销量同期变动情况:

Change in sales volume of domestic formulation products over the same period:



股东信息

Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名普通股股东及表决权恢复的优先股股东总数 (I) Total number of common shareholders and the number of preferred shareholders whose voting rights were restored and the top ten shareholders' shareholdings

报告期末普通股股东总数 Total number of ordinary shareholders by the end of the reporting period		报告期末表决权恢复的优先股股东总数(如有) Total number of preferred shareholders whose voting rights were restored at the end of the reporting period		单位: 股 Unit: Share	
前10名股东持股情况 Shareholdings of the top ten shareholders					
股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares	持股比例(%) Shareholding ratio (%)	持有有限售条件股份数量 Number of shares held with selling restrictions	质押、标记或冻结情况 Status of shares pledged, tagged or frozen
甘忠如	境内自然人 Domestic natural person	177,135,207	31.32	177,135,207	无 None
明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	境外法人 Overseas legal entity	56,272,661	9.95	15,875,800	无 None
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co., Ltd.	境内非国有法人 Domestic non-state-owned legal entity	47,494,437	8.40	47,494,437	无 None
Vast Wintersweet Limited	境外法人 Overseas legal entity	32,481,638	5.74	5,777,913	无 None
STRONG LINK INTERNATIONAL LIMITED	国有法人 State-owned legal entity	8,121,533	1.44	4,256,033	无 None
甘喜茹	境内自然人 Domestic natural person	6,223,276	1.10	6,223,276	无 None
GS Direct,L.L.C.	境外法人 Overseas legal entity	5,316,690	0.94	1,968,822	无 None
Hillhouse G&L Holdings (HK) Limited	境外法人 Overseas legal entity	4,357,832	0.77	4,296,032	无 None
北京宽街博华投资中心(有限合伙) Beijing Kuanjie Bohua Investment Center (L.P)	其他 Others	3,905,161	0.69	1,390,961	无 None
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited－China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	其他 Others	3,494,920	0.62	0	无 None

前10名无限售条件股东持股情况 The shareholding of top ten shareholders of non-restricted shares				单位：股 Unit: Share
股东名称 Shareholder name	持有无限售条件流通股的数量 Numbers of shares held without trading limited conditions	股份种类 Category	股份种类及数量 Category and Number of shares	数量 Number
明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	40,396,861	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	40,396,861
Vast Wintersweet Limited	26,703,725	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	26,703,725
STRONG LINK INTERNATIONAL LIMITED	3,865,500	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	3,865,500
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	3,494,920	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	3,494,920
GS Direct,L.L.C.	3,347,868	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	3,347,868
招商银行股份有限公司－南方阿尔法混合型证券投资基金 China Merchants Bank Co., Ltd.-Southern Alpha Hybrid Securities Investment Fund	2,824,384	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	2,824,384
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	2,602,564	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	2,602,564
北京宽街博华投资中心(有限合伙) Beijing Kuanjie Bohua Investment Center(L.P.)	2,514,200	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	2,514,200
上海原泽私募基金管理有限公司－原泽明志1号私募证券投资基金 Shanghai Yuanze Private Equity Fund Management Co., Ltd - Yuanze Mingzhi No.1 Private Equity Investment Fund	2,395,300	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	2,395,300
甘一如 Gan Yiru	2,215,637	人民币普通股 RMB ordinary shares	人民币普通股 RMB ordinary shares	2,215,637
上述股东关联关系或一致行动的说明 Explanation of the related relationship or concerted action of the above shareholders			公司控股股东、实际控制人甘一如持有旭特宏达65.02%的股权；甘喜茹为甘忠如胞妹；GS Direct与宽街博华的实际控制人均均为The Goldman Sachs Group,Inc (高盛集团)。除以上情况外，其他股东之间不存在关联关系或一致行动。 Gan Zhongru, the controlling shareholder and actual controller of the Company, holds 65.02% of the shares of Xutehongda; GanXiru is GanZhongRu's sister;the actual controllers of GS Direct and Kuanjie Bohua are The Goldman Sachs Group, Inc (Goldman Sachs Group); there is no associated relationship or concerted action among other shareholders.	
前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有) Explanation on the participation of the top ten shareholders and the top ten shareholders with unrestricted shares in the margin financing and securities lending and refinancing business (if any)			无 None	

其他提醒事项

Other Reminders



三、其他提醒事项

需提醒投资者关注的关于公司报告期经营情况的其他重要信息

适用 不适用

III Other reminders

Other important information that investors need to be reminded of about the company's operation during the reporting period.

Applicable Not Applicable

季度财务报表

Quarterly Financial Statements



四、季度财务报表

IV Quarterly Financial Statements

(一) 审计意见类型

(I) Types of audit opinions

□ 适用 √ 不适用

□ Applicable √ Not Applicable

(二) 财务报表

(II) Financial statements

合并资产负债表

Consolidated Balance Sheets

2023年3月31日
31 March 2023编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2023年3月31日 March 31, 2023	2022年12月31日 December 31, 2022
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	2,743,913,570.30	2,890,266,792.18
交易性金融资产	Financial assets held for trading	1,648,613,330.66	1,635,949,901.34
应收账款	Accounts receivable	206,154,418.90	176,251,160.43
应收款项融资	Receivables financing	29,474,845.04	13,316,425.56
预付款项	Prepayments	49,219,117.27	45,978,647.53
其他应收款	Other receivables	4,022,733.14	5,888,971.68
存货	Inventories	688,682,017.41	648,645,609.14
一年内到期的非流动资产	Non-current assets due within one year	201,332,602.74	201,358,630.13
其他流动资产	Other current assets	52,988,520.49	46,480,151.30
流动资产合计	Total current assets	5,624,401,155.95	5,664,136,289.29
非流动资产:	Non-current Assets:		
其他非流动金融资产	Other non-current financial assets	30,000,000.00	30,000,000.00
固定资产	Fixed assets	1,832,315,489.03	1,646,528,285.07
在建工程	Construction in progress	1,825,876,533.40	2,002,728,242.12
使用权资产	Right-of-use assets	10,844,134.09	12,080,372.03
无形资产	Intangible assets	286,375,929.65	293,480,707.13
开发支出	Development expenditures	763,195,658.48	732,562,121.88
长期待摊费用	Long-term deferred expenses	10,188,537.25	10,632,701.96
递延所得税资产	Deferred tax assets	129,840,423.54	138,250,375.69
其他非流动资产	Other non-current assets	82,839,345.01	76,513,284.89
非流动资产合计	Total non-current assets	4,971,476,050.45	4,942,776,090.77
资产总计	Total assets	10,595,877,206.40	10,606,912,380.06

合并资产负债表 (续)

Consolidated Balance Sheets (Continued)

项目	Item	2023年3月31日 March 31, 2023	2022年12月31日 December 31, 2022
流动负债:	Current Liabilities		
应付账款	Accounts payable	86,498,900.23	44,692,994.55
预收款项	Deposit received	251,992.33	603,555.70
合同负债	Contract liabilities	55,236,881.87	68,125,067.69
应付职工薪酬	Employee compensation payable	154,687,740.62	142,022,574.85
应交税费	Taxes payable	12,649,650.38	14,413,032.33
其他应付款	Other payables	425,058,907.73	534,680,233.19
一年内到期的非流动负债	Non-current liabilities due within one year	8,960,940.95	7,563,363.97
其他流动负债	Other current liabilities	361,262.21	936,179.18
流动负债合计	Total current liabilities	743,706,276.32	813,037,001.46
非流动负债:	Non-current Liabilities:		
租赁负债	Lease liabilities	8,066,225.81	8,327,140.36
长期应付款	Long-term payable	11,427,974.65	12,274,100.29
递延收益	Deferred income	187,379,065.12	187,634,504.08
非流动负债合计	Total non-current liabilities	206,873,265.58	208,235,744.73
负债合计	Total liabilities	950,579,541.90	1,021,272,746.19
所有者权益(或股东权益):	Owners equity (or shareholders' equity):		
实收资本(或股本)	Paid-in capital (or share capital)	565,653,200.00	565,653,200.00
资本公积	Capital reserve	2,574,560,120.12	2,563,002,386.27
减: 库存股	Less: Treasury stocks	71,364,020.00	71,364,020.00
其他综合收益	Other comprehensive income	2,319,207.74	3,442,128.87
盈余公积	Surplus reserve	291,531,843.96	291,531,843.96
未分配利润	Retained earnings	6,282,759,871.69	6,233,536,610.40
归属于母公司所有者权益(或股东权益)合计	Total owner's equity (or shareholders' equity) attributable to the parent company	9,645,460,223.51	9,585,802,149.50
少数股东权益	Non-controlling interests	-162,559.01	-162,515.63
所有者权益(或股东权益)合计	Total owners' equity (or shareholders' equity)	9,645,297,664.50	9,585,639,633.87
负债和所有者权益(或股东权益)总计	Total Liabilities and owners' equity (or shareholders' equity)	10,595,877,206.40	10,606,912,380.06

公司负责人:	甘忠如	主管会计工作负责人:	孙程	会计机构负责人:	周丽
Legal Representative:	Gan Zhongru	Chief accountant:	Sun Cheng	Head of accounting department:	Zhou Li

合并利润表

Consolidated Income Statement

2023年1—3月
Jan to Mar, 2023编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2023年第一季度 The first quarters in 2023	2022年第一季度 The first quarters in 2022
一、营业总收入	I. Total Revenue	557,999,537.96	689,990,891.63
其中:营业收入	Including: Operating income	557,999,537.96	689,990,891.63
二、营业总成本	II. Total Cost of sales	528,077,591.01	500,134,589.51
其中:营业成本	Including: Cost of sales	150,830,624.26	60,353,311.34
税金及附加	Taxes and surcharges	6,061,051.09	5,967,119.29
销售费用	Selling expenses	224,729,850.74	288,064,449.59
管理费用	General and administrative expenses	46,800,804.48	70,735,565.35
研发费用	R&D expenses	119,936,250.47	97,888,052.81
财务费用	Financial expenses	-20,280,990.03	-22,873,908.87
加:其他收益	Add: Other income	5,295,268.14	5,260,387.01
投资收益(损失以“—”号填列)	Investment income/(loss) (loss is indicated with “-”)	1,578,563.69	5,634,860.83
公允价值变动收益(损失以“—”号填列)	Gain/(loss) on the changes in fair value (loss is indicated with “-”)	17,706,102.62	-64,757,459.49
信用减值损失(损失以“—”号填列)	Credit impairment losses (loss is indicated with “-”)	5,183,449.30	825,510.79
资产处置收益(损失以“—”号填列)	Gain/(loss) from disposal of assets (loss is indicated with “-”)	140,716.06	
三、营业利润(亏损以“—”号填列)	III. Operating Profit (loss is indicated with “-”)	59,826,046.76	136,819,601.26
加:营业外收入	Add: Non-operating income	72,251.09	58,383.38
减:营业外支出	Less: Non-operating expenses	2,207,715.29	24,746.31
四、利润总额(亏损总额以“—”号填列)	IV. Total Profit (loss is indicated with “-”)	57,690,582.56	136,853,238.33
减:所得税费用	Less: Income tax expense	8,467,364.65	23,555,729.35
五、净利润(净亏损以“—”号填列)	V. Net Profit (loss is indicated with “-”)	49,223,217.91	113,297,508.98
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“—”号填列)	1. Net profit from continuing operations (loss is indicated with “-”)	49,223,217.91	113,297,508.98

合并利润表 (续)

Consolidated Income Statement (Continued)

项目	Item	2023年第一季度 The first quarters in 2023	2022年第一季度 The first quarters in 2022
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润 (净亏损以“-”号填列)	1. Net profit attributable to owners of the parent company (loss is indicated with "-")	49,223,261.29	113,297,551.23
2. 少数股东损益 (净亏损以“-”号填列)	2. Net profit attributable to non- controlling interests (loss is indicated with "-")	-43.38	-42.25
六、其他综合收益的税后净额	VI. Other Comprehensive Income, Net of Tax	-1,122,921.13	-316,366.84
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, attributable to owners of the parent company, net of tax	-1,122,921.13	-316,366.84
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income that will not be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified into profit or loss	-1,122,921.13	-316,366.84
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-1,122,921.13	-316,366.84
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income, net of tax, attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	48,100,296.78	112,981,142.14
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	48,100,340.16	112,981,184.39
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-43.38	-42.25
八、每股收益：	VIII. Earnings Per Share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (RMB/share)	0.09	0.20
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (RMB/share)	0.09	0.20

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

For business combination involving entities under common control occurred during the period, net profit of the acquiree generated before the business combination is RMB 0.00, and net profit of the acquiree generated in prior period is RMB 0.00.

公司负责人：甘忠如 主管会计工作负责人：孙程 会计机构负责人：周丽
 Legal Representative: Gan Zhongru Chief accountant: Sun Cheng Head of accounting department: Zhou Li

合并现金流量表

Consolidated Statement of Cash Flows

2023年1—3月
Jan to Mar, 2023编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2023年第一季度 The first quarters in 2023	2022年第一季度 The first quarters in 2022
一、经营活动产生的现金流量:	I. Cash Flows from Operating Activities:		
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	521,288,359.88	894,205,993.69
收到的税费返还	Tax refunds received	19,057,286.19	523,813.80
收到其他与经营活动有关的现金	Cash received relating to other operating activities	6,532,168.71	33,167,284.87
经营活动现金流入小计	Subtotal of cash inflows from operating activities	546,877,814.78	927,897,092.36
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	141,805,607.71	133,432,787.74
支付给职工及为职工支付的现金	Cash paid to and on behalf of employee	187,822,557.25	168,656,892.91
支付的各项税费	Cash paid for taxes	29,372,680.15	134,932,440.84
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	204,137,090.44	257,794,910.75
经营活动现金流出小计	Sub-total of cash outflows from operating activities	563,137,935.55	694,817,032.24
经营活动产生的现金流量净额	Net cash flows from operating activities	-16,260,120.77	233,080,060.12
二、投资活动产生的现金流量:	II. Cash Flows from Investing Activities:		
收回投资收到的现金	Cash received from disposal of investments	1,514,973,800.44	880,000,000.00
取得投资收益收到的现金	Cash receipts from investment income	11,921,797.48	23,927,713.47
处置固定资产、无形资产和其他长期资产收回的现金净额	Net cash received from disposal of fixed assets, intangibles and other long-term assets	180,000.00	
收到其他与投资活动有关的现金	Cash received in connection with other investing activities	11,614,356.00	
投资活动现金流入小计	Sub-total of cash inflows from investing activities	1,538,689,953.92	903,927,713.47
购建固定资产、无形资产和其他长期资产支付的现金	Cash paid for the purchase and construction of fixed assets, intangibles and other long-term assets	139,562,957.82	156,037,532.25
投资支付的现金	Cash paid for investments	1,415,230,133.28	1,080,000,000.00
支付其他与投资活动有关的现金	Cash paid relating to other investing activities	29,303,715.60	10,376,176.18
投资活动现金流出小计	Subtotal of cash outflows from investing activities	1,584,096,806.70	1,246,413,708.43
投资活动产生的现金流量净额	Net cash flows from investing activities	-45,406,852.78	-342,485,994.96

合并现金流量表 (续)

Consolidated Statement of Cash Flows (Continued)

项目	Item	2023年第一季度 The first quarters in 2023	2022年第一季度 The first quarters in 2022
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
吸收投资收到的现金	Cash received from investments		
筹资活动现金流入小计	Subtotal of cash inflows		
分配股利、利润或偿付利息支付的现金	Cash paid for distribution of dividends, profits or interest payments		
支付其他与筹资活动有关的现金	Cash paid for other financing activities	918,525.58	220,098.80
筹资活动现金流出小计	Subtotal of cash outflows from financing activities	918,525.58	220,098.80
筹资活动产生的现金流量净额	Net cash flow from financing activities	-918,525.58	-220,098.80
四、汇率变动对现金及现金等价物的影响	IV. Effect of Exchange Rate Changes on Cash and Cash Equivalents	-1,585,949.98	-725,646.21
五、现金及现金等价物净增加额	V. Net Increase in Cash and Cash Equivalents	-64,171,449.11	-110,351,679.85
加：期初现金及现金等价物余额	Add: balance of cash and cash equivalents at the beginning of the period	397,328,882.98	639,768,344.07
六、期末现金及现金等价物余额	VI. Balance of cash and cash equivalents at the end of the period	333,157,433.87	529,416,664.22

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Gan Zhongru	Chief accountant:	Sun Cheng	Head of accounting department:	Zhou Li

(三) 2023年起首次执行新会计准则或准则解释等涉及调整首次执行当年年初的财务报表√ 适用 不适用

调整当年年初财务报表的原因说明

2022年，财政部发布了《企业会计准则解释第16号》(财会〔2022〕31号，以下简称“解释16号”)，其中“关于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理”规定，自2023年1月1日起施行。

公司自2023年1月1日起施行解释16号，并根据准则解释要求，对因适用该解释的单项交易而确认的租赁负债和使用权资产，产生的应纳税暂时性差异和可抵扣暂时性差异，按照该解释和《企业会计准则第18号——所得税》的规定，将累计影响数调整财务报表列报最早期间的期初留存收益及其他相关财务报表项目。

(III) First-time implementation of new accounting standards or interpretations of standards from 2023 onwards involving adjustments to the financial statements at the beginning of the year of first-time implementation√ Applicable Not Applicable

Statement of reasons for adjusting the financial statements at the beginning of the year

In 2022, the Ministry of Finance issued Interpretation of ASBE No.16 (Caikuai [2022] No.31, hereinafter referred to as "Interpretation of No.16"), which provides for "Accounting for Deferred Income Taxes Associated with Assets and Liabilities Arising from a Single Transaction without Applying the Initial Recognition Exemption", effective from 1 January 2023.

The Company applied Interpretation of No.16 effective January 1, 2023, and as required by the interpretation of the standard, the cumulative effect of taxable temporary differences and deductible temporary differences arising from lease liabilities and right-of-use assets recognized as a result of the individual transactions to which the interpretation applies is adjusted to opening retained earnings and other related financial statement items in the earliest period presented in the financial statements in accordance with the provisions of the interpretation and ASBE No.18 - Income Taxes.

合并资产负债表
Consolidated Balance Sheets

单位：元 币种：人民币
Unit: RMB

项目	Item	2022年12月31日 December 31, 2022	2023年1月1日 January 1, 2023	调整数 Number of adjustments
流动资产：				
Current Assets:				
货币资金	Cash and Cash equivalents	2,890,266,792.18	2,890,266,792.18	
交易性金融资产	Financial assets held for trading	1,635,949,901.34	1,635,949,901.34	
应收账款	Accounts receivable	176,251,160.43	176,251,160.43	
应收款项融资	Receivables financing	13,316,425.56	13,316,425.56	
预付款项	Prepayments	45,978,647.53	45,978,647.53	
其他应收款	Other receivables	5,888,971.68	5,888,971.68	
存货	Inventories	648,645,609.14	648,645,609.14	
一年内到期的非流动资产	Non-current assets due within one year	201,358,630.13	201,358,630.13	
其他流动资产	Other current assets	46,480,151.30	46,480,151.30	
流动资产合计	Total current assets	5,664,136,289.29	5,664,136,289.29	
非流动资产：				
Non-current Assets:				
其他非流动金融资产	Other non-current financial assets	30,000,000.00	30,000,000.00	
固定资产	Fixed assets	1,646,528,285.07	1,646,528,285.07	
在建工程	Construction in progress	2,002,728,242.12	2,002,728,242.12	
使用权资产	Right-of-use assets	12,080,372.03	12,080,372.03	
无形资产	Intangible assets	293,480,707.13	293,480,707.13	
开发支出	Development expenditures	732,562,121.88	732,562,121.88	
长期待摊费用	Long-term deferred expenses	10,632,701.96	10,632,701.96	
递延所得税资产	Deferred tax assets	138,250,375.69	138,250,375.69	
其他非流动资产	Other non-current assets	76,513,284.89	76,513,284.89	
非流动资产合计	Total non-current assets	4,942,776,090.77	4,942,776,090.77	
资产总计	Total assets	10,606,912,380.06	10,606,912,380.06	
流动负债：				
Current liabilities:				
应付账款	Accounts payable	44,692,994.55	44,692,994.55	
预收款项	Deposit received	603,555.70	603,555.70	
合同负债	Contract liabilities	68,125,067.69	68,125,067.69	
应付职工薪酬	Employee compensation payable	142,022,574.85	142,022,574.85	
应交税费	Taxes payable	14,413,032.33	14,413,032.33	
其他应付款	Other payables	534,680,233.19	534,680,233.19	
一年内到期的非流动负债	Non-current liabilities due within one year	7,563,363.97	7,563,363.97	

合并资产负债表 (续)

Consolidated Balance Sheets (Continued)

项目	Item	2022年12月31日 December 31, 2022	2023年1月1日 January 1, 2023	调整数 Number of adjustments
其他流动负债	Other current liabilities	936,179.18	936,179.18	
流动负债合计	Total current liabilities	813,037,001.46	813,037,001.46	
非流动负债:	Non-current Liabilities:			
租赁负债	Lease liabilities	8,327,140.36	8,327,140.36	
长期应付款	Long-term payable	12,274,100.29	12,274,100.29	
递延收益	Deferred income	187,634,504.08	187,634,504.08	
递延所得税负债	Deferred tax liabilities			
非流动负债合计	Total non-current liabilities	208,235,744.73	208,235,744.73	
负债合计	Total liabilities	1,021,272,746.19	1,021,272,746.19	
所有者权益(或股东权益):	Owners equity (or shareholders' equity):			
实收资本(或股本)	Paid-in capital (or share capital)	565,653,200.00	565,653,200.00	
资本公积	Capital reserve	2,563,002,386.27	2,563,002,386.27	
减: 库存股	Less: Treasury stocks	71,364,020.00	71,364,020.00	
其他综合收益	Other comprehensive income	3,442,128.87	3,442,128.87	
盈余公积	Surplus reserve	291,531,843.96	291,531,843.96	
未分配利润	Retained earnings	6,233,536,610.40	6,233,536,610.40	
归属于母公司所有者权益 (或股东权益) 合计	Total owner's equity (or shareholders' equity) attributable to the parent company	9,585,802,149.50	9,585,802,149.50	
少数股东权益	Non-controlling interests	-162,515.63	-162,515.63	
所有者权益(或股东权益) 合计	Total owners' equity (or shareholders' equity)	9,585,639,633.87	9,585,639,633.87	
负债和所有者权益(或股东 权益) 总计	Total Liabilities and owners' equity (or shareholders' equity)	10,606,912,380.06	10,606,912,380.06	

说明：

对2023年1月1日递延所得税资产的影响为：未经抵销的递延所得税资产增加1,588,573.11元、递延所得税资产和负债期末互抵金额增加1,588,573.11元、抵销后净额列示的递延所得税资产增加0.00元。

对2023年1月1日递延所得税负债的影响为：未经抵销的递延所得税负债增加1,588,573.11元、递延所得税资产和负债期末互抵金额增加1,588,573.11元、抵销后净额列示的递延所得税负债增加0.00元。

Notes:

The impact on deferred tax assets at January 1, 2023 is an increase in deferred tax assets without offset of RMB 1,588,573.11, an increase in the amount of deferred tax assets and liabilities offset at the end of the period of RMB 1,588,573.11 and an increase in deferred tax assets presented net of offset of RMB 0.00.

The effect on deferred tax liabilities at January 1, 2023 was an increase in unset-off deferred tax liabilities of RMB 1,588,573.11, an increase in the amount of deferred tax assets and liabilities offset at the end of the period of RMB 1,588,573.11 and an increase in deferred tax liabilities presented net of offset of RMB 0.00.

特此公告

Hereby notify the above notify.

甘李药业股份有限公司董事会
Gan & Lee Pharmaceuticals. Board of Directors

2023年4月26日
26/4/2023



SCIENCE & EXCELLENCE

甘李药业有限公司

地址：北京市通州区潮集镇南凤西一路8号

网址：<http://www.ganlee.com>

电话：+86 010-80593699

邮编：101109